Survey suggests cautious welcome for oral MS drugs
From the MS Trust
A survey of American neurologists suggests a cautious welcome for the oral MS drugs currently in development should they be approved.
Of the 75 neurologists questioned, 60% mentioned concerns about side effects and safety issues associated with the emerging treatments. However, 84% recognised that the drugs were more effective than the current treatments and would prescribe them, although they expected they would not be a first-line therapy until concerns about safety were resolved. It was felt that patients would consider them more convenient that the current injections.